.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Citi
US Army
Teva
Dow
Novartis
UBS
Boehringer Ingelheim
Farmers Insurance

Generated: September 24, 2017

DrugPatentWatch Database Preview

Fingolimod - Generic Drug Details

« Back to Dashboard

What are the generic sources for fingolimod and what is the scope of fingolimod freedom to operate?

Fingolimod
is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Fingolimod has one hundred and twenty-nine patent family members in forty-one countries.

There are eighteen drug master file entries for fingolimod. One supplier is listed for this compound. There are two tentative approvals for this compound.

Summary for Generic Name: fingolimod

Tradenames:1
Patents:4
Applicants:1
NDAs:1
Drug Master File Entries: see list18
Suppliers / Packagers: see list1
Bulk Api Vendors: see list41
Clinical Trials: see list51
Patent Applications: see list2,304
Drug Prices:see low prices
DailyMed Link:fingolimod at DailyMed

Pharmacology for Ingredient: fingolimod

Tentative approvals for FINGOLIMOD

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe0.5MGCAPSULE;ORAL
► Subscribe► Subscribe0.5MGCAPSULE;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
GILENYA
fingolimod
CAPSULE;ORAL022527-001Sep 21, 2010RXYesYes► Subscribe► SubscribeY ► Subscribe
Novartis
GILENYA
fingolimod
CAPSULE;ORAL022527-001Sep 21, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Novartis
GILENYA
fingolimod
CAPSULE;ORAL022527-001Sep 21, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Novartis
GILENYA
fingolimod
CAPSULE;ORAL022527-001Sep 21, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: fingolimod

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
GILENYA
fingolimod
CAPSULE;ORAL022527-001Sep 21, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: fingolimod

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,719,176 2-amino-1,3-propanediol compound and immunosuppressant► Subscribe
8,741,963S1P receptor modulators for treating multiple sclerosis► Subscribe
6,667,025 Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties► Subscribe
5,952,316 2-amino-1,3-propanediol compound and immunosuppressant► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: fingolimod

Country Document Number Estimated Expiration
CroatiaP20100601► Subscribe
China1767819► Subscribe
South Korea20120101148► Subscribe
European Patent Office2769713► Subscribe
Russian Federation2617502► Subscribe
MexicoPA05010860► Subscribe
Germany602004017847► Subscribe
Spain2556947► Subscribe
New Zealand542622► Subscribe
Taiwan200503784► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FINGOLIMOD

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0110013 00043Estonia► SubscribePRODUCT NAME: GILENYA - FINGOLIMOD; REG NO/DATE: FINAL 17.03.2011
0627406/01Switzerland► SubscribeFORMER REPRESENTATIVE: BOHEST AG, CH
1613288/01Switzerland► SubscribeFORMER REPRESENTATIVE: BOHEST AG, CH
90025-5Sweden► SubscribePRODUCT NAME: FINGOLIMOD; REG. NO/DATE: EU/1/11/677/001-003 20110317
C/GB11/026United Kingdom► SubscribePRODUCT NAME: FINGOLIMOD, I.E. 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DIOL, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/677/001 20110317; UK EU/1/11/677/002 20110317; UK EU/1/11/677/003 20110317; UK EU/1/11/677/004 20110317
2011 00015Denmark► Subscribe
2011 00023Denmark► Subscribe
C0021France► SubscribePRODUCT NAME: FINGOLIMOD ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES EN PARTICULIER SON CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/11/677/001 20110317
867Luxembourg► Subscribe91867, EXPIRES: 20260317
2011010Lithuania► SubscribePRODUCT NAME: FINGOLIMODUM; REGISTRATION NO/DATE: EU/1/11/677/001, 2011 03 17 EU/1/11/677/002, 2011 03 17 EU/1/11/677/003, 2011 03 17 EU/1/11/677/004 20110317
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
McKesson
Farmers Insurance
Boehringer Ingelheim
Julphar
Cantor Fitzgerald
Medtronic
Accenture
UBS
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot